Cantor Fitzgerald analyst Ross Osborn initiated coverage of MiMedx with an Overweight rating and $11 price target. Cantor holds a favorable view of the estimated $3.9B Advanced Wound Care and Surgical Markets and believes MiMedx’s offerings are differentiated and protected given their strong clinical data, the analyst tells investors in a research note. In addition, Cantor views the company’s shares as attractively valued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: